Cargando…
The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates
HER2-positive breast cancer is an aggressive disease. As a result of the development of specific HER2-targeted therapies, such as trastuzumab, more than 20 years ago, the prognosis of these patients has improved. Metastatic HER2-positive breast cancer patients are achieving better survival rates upo...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099594/ https://www.ncbi.nlm.nih.gov/pubmed/37065870 http://dx.doi.org/10.20517/cdr.2022.52 |